Get the latest news, insights, and market updates on NTRA (Natera, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
How Investors Are Reacting To Natera (NTRA) Trial Data Showing Signatera’s 40% Risk Reduction In CRC
Natera recently reported multiple clinical data readouts, including JAMA Oncology publication of the phase III CALGB/SWOG 80702 trial, showing that adding celecoxib to standard chemotherapy cut recurrence and death risk by about 40% in Signatera-positive stage III colorectal cancer patients. Across colorectal and breast cancer studies, Signatera’s personalized ctDNA platform consistently refined risk stratification and treatment response prediction, underscoring its potential role in guiding... Dec 20, 2025 - $NTRA
Natera (NTRA): Assessing Valuation After a Multi‑Year Share Price Surge
Natera (NTRA) has quietly delivered a strong run over the past year, with the stock climbing more than 40% as investors lean into its growth in genetic testing and cancer diagnostics. See our latest analysis for Natera. That momentum has been building rather than fading, with a 28.08% 3 month share price return and a standout 458.40% 3 year total shareholder return signaling that investors are steadily repricing Natera as growth in testing scales. If Natera has you rethinking what strong... Dec 20, 2025 - $NTRA
Natera Announces Publication of Signatera™ Analysis from Randomized, Phase III CALGB (Alliance)/SWOG 80702 Study in Colorectal Cancer
AUSTIN, Texas, December 18, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of findings from the randomized, phase III CALGB (Alliance)/SWOG 80702 study in JAMA Oncology. This publication builds on the initial presentation of results at the 2025 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI) earlier this year. Dec 18, 2025 - $NTRA
Natera and MEDSIR to Collaborate on the MiRaDoR Trial in Breast Cancer
AUSTIN, Texas, December 12, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their collaboration on the MiRaDoR (NCT05708235) study, which is a multicenter, phase II clinical trial in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer. Dec 12, 2025 - $NTRA
Is It Too Late To Consider Natera After Its Recent 12.8% Price Surge?
If you are wondering whether Natera’s soaring share price still leaves room for upside, or if the easy money has already been made, you are in the right place to unpack what the market is really pricing in. Even after a strong multi year run, with the stock up 511.2% over 3 years and 45.2% year to date, the recent 12.8% gain over 30 days followed by a 3.7% pullback in the last week suggests investors are still actively reassessing the risk reward profile. Recent moves have been shaped by... Dec 11, 2025 - $NTRA
Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks
Stanley Druckenmiller is a Wall Street legend whose trades are truly worth tracking due to how consistently he has been winning. He has been piling into Natera (NASDAQ:NTRA), Insmed (NASDAQ:INSM), and Teva Pharmaceuticals (NYSE:TEVA) as of late, and we’ll get into why. Druckenmiller first gained fame by managing George Soros’s Quantum Fund, where he orchestrated ... Billionaire Stanley Druckenmiller is Betting $1.2 Billion in These 3 Stocks Dec 11, 2025 - $NTRA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple